News | May 19, 2026
Lupin debuts in Dow Jones best-in-class indices for ESG performance
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The product is approved as bioequivalent to Xigduo XR for the indications outlined in the reference drug’s labelling
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
